Molecular Partners AG ADR (MOLN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $112.71M
Last updated: Nov 17, 2026 at 10:12 AM ET
Molecular Partners AG ADR (MOLN) Competitors
The companies most similar to Molecular Partners AG ADR are Pmv Pharmaceuticals (PMVP), Invivyd (IVVD) and MacroGenics (MGNX). By market cap, Molecular Partners AG ADR ranks 10th of the 13 companies on this page; Invivyd (IVVD) is the largest at $171.58M.
Peer Comparison
MOLN's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Molecular Partners AG ADR (MOLN) | $112.71M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Pmv Pharmaceuticals Inc (PMVP) | $95.93M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| PDS Biotechnology Corp (PDSB) | $107.07M | N/A | N/A | 0.0% | -149.8% | 0.0% | 0.00% |
| LENZ Therapeutics Inc (LENZ) | $129.77M | N/A | 9.7x | 0.0% | N/A | -72.9% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Minerva Neurosciences Inc (NERV) | $114.62M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Zentalis Pharmaceuticals Llc (ZNTL) | $167.05M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| PolyPid (PYPD) | $132.25M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Tiziana Life Sciences Ltd (TLSA) | $72.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $135.80M | N/A | 9.7x | 0.0% | -108.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Molecular Partners AG ADR, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Pmv Pharmaceuticals Inc (PMVP) | PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53... | PMVP competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| PDS Biotechnology Corp (PDSB) | PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. | PDSB competitors |
| LENZ Therapeutics Inc (LENZ) | LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders... | LENZ competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Minerva Neurosciences Inc (NERV) | Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products... | NERV competitors |
| Zentalis Pharmaceuticals Llc (ZNTL) | Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment... | ZNTL competitors |
| PolyPid (PYPD) | PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)... | PYPD competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
| Tiziana Life Sciences Ltd (TLSA) | Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat... |
Frequently Asked Questions About MOLN
Who are Molecular Partners AG ADR's main competitors?
The companies most similar to Molecular Partners AG ADR include Pmv Pharmaceuticals (PMVP), Invivyd (IVVD), MacroGenics (MGNX), PDS Biotechnology (PDSB) and LENZ Therapeutics (LENZ), listed from the closest match.
Who is Molecular Partners AG ADR's biggest competitor?
Invivyd (IVVD) is the largest of the similar companies at $171.58M; Pmv Pharmaceuticals (PMVP) is the closest match by business profile, size, sector and industry.
How does MOLN stock compare with its competitors?
MOLN's net margin is 0.0% against a peer median of 0.0%.
Which of Molecular Partners AG ADR's competitors pays a higher dividend?
Molecular Partners AG ADR pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Molecular Partners AG ADR bigger than its competitors?
No. Molecular Partners AG ADR is 10th by market cap among the 13 companies on this page; the largest is Invivyd (IVVD) at $171.58M.
MOLN pages: Overview, Financials, Competitors